Distribution of circulating tumor cell phenotype in early cervical cancer

References

• Watson M, Benard V, Thomas C, Brayboy A, Paisano R, Becker T. Cervical cancer incidence and mortality among American Indian and Alaska Native women, 1999-2009. Am J Public Health. 2014;104(Suppl 3):S415–S422. doi:10.2105/AJPH.2014.30216724754650
   PubMedGoogle Scholar
• Obel J, Souares Y, Hoy D, et al. A systematic review of cervical cancer incidence and mortality in the Pacific Region. Asian Pac J Cancer Prev. 2014;15(21):9433–9437.25422237
   PubMedGoogle Scholar
• Benard VB, Thomas CC, King J, et al. Vital signs: cervical cancer incidence, mortality, and screening - United States, 2007-2012. MMWR Morb Mortal Wkly Rep. 2014;63(44):1004–1009.25375072
   PubMed Web of Science ®Google Scholar
• Li TT, Liu H, Yu J, Shi GY, Zhao LY, Li GX. Prognostic and predictive blood biomarkers in gastric cancer and the potential application of circulating tumor cells. World J Gastroenterol. 2018;24(21):2236–2246. doi:10.3748/wjg.v24.i21.223629881233
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Chekhonin VP. Circulating tumor cells and their advances to promote cancer metastasis and relapse, with focus on glioblastoma multiforme. Exp Mol Pathol. 2018;105(2):166–174. doi:10.1016/j.yexmp.2018.07.00730028961
   PubMed Web of Science ®Google Scholar
• Burz C, Pop VV, Buiga R, et al. Circulating tumor cells in clinical research and monitoring patients with colorectal cancer. Oncotarget. 2018;9(36):24561–24571. doi:10.18632/oncotarget.2533729849961
   PubMedGoogle Scholar
• Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer. 2004;4(6):448–456. doi:10.1038/nrc137015170447
   PubMed Web of Science ®Google Scholar
• Alixpanabières C, Pantel K. Liquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay. Expert Rev Mol Diagn. 2015;15(11):1411–1417. doi:10.1586/14737159.2015.109172926390240
   PubMed Web of Science ®Google Scholar
• Krawczyk N, Fehm T, Banys-Paluchowski M, Janni W, Schramm A. Liquid biopsy in metastasized breast cancer as basis for treatment decisions. Oncol Res Treat. 2016;39(3):112–116. doi:10.1159/00044460527031542
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–791. doi:10.1056/NEJMoa04076615317891
   PubMed Web of Science ®Google Scholar
• Bu XM, Xu FF, Ma J, Jiang B. The expression of circulating tumor cells in peripheral blood of patients with non-small cell lung cancer and its detection. J Biol Regul Homeost Agents. 2018;32(4):843–849.30043565
   PubMed Web of Science ®Google Scholar
• Bracht JWP, Mayo-de-Las-Casas C, Berenguer J, Karachaliou N, Rosell R. The present and future of liquid biopsies in non-small cell lung cancer: combining four biosources for diagnosis, prognosis, prediction, and disease monitoring. Curr Oncol Rep. 2018;20(9):70. doi:10.1007/s11912-018-0720-z30030656
   PubMed Web of Science ®Google Scholar
• Wang W, Wan L, Wu S, et al. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis. Cell Oncol (Dordr). 2018;41(5):495–504. doi:10.1007/s13402-018-0386-429949050
   PubMed Web of Science ®Google Scholar
• Hashimoto M, Tanaka F, Yoneda K, et al. The clinical value of circulating tumour cells (CTCs) in patients undergoing pulmonary metastasectomy for metastatic colorectal cancer. J Thorac Dis. 2018;10(3):1569–1577. doi:10.21037/jtd.2018.03.0529707308
   PubMed Web of Science ®Google Scholar
• Liu X, Li C, Li J, et al. Detection of CTCs in portal vein was associated with intrahepatic metastases and prognosis in patients with advanced pancreatic cancer. J Cancer. 2018;9(11):2038–2045. doi:10.7150/jca.2398929896289
   PubMed Web of Science ®Google Scholar
• Court CM, Ankeny JS, Sho S, et al. Circulating tumor cells predict occult metastatic disease and prognosis in pancreatic cancer. Ann Surg Oncol. 2018;25(4):1000–1008. doi:10.1245/s10434-017-6290-829442211
   PubMed Web of Science ®Google Scholar
• Willecke-Hochmuth R, Pachmann K, Drevs J. Treatment of advanced solid tumours with NSAIDs: correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imaging. Oncol Lett. 2016;12(3):1711–1716. doi:10.3892/ol.2016.487827588120
   PubMed Web of Science ®Google Scholar
• Ma B, King AD, Leung L, et al. Identifying an early indicator of drug efficacy in patients with metastatic colorectal cancer-a prospective evaluation of circulating tumor cells, 18F-fluorodeoxyglucose positron-emission tomography and the RECIST criteria. Ann Oncol. 2017;28(7):1576–1581. doi:10.1093/annonc/mdx14928379285
   PubMed Web of Science ®Google Scholar
• Bayarri-Lara CI, de Miguel Perez D, Cueto Ladron de Guevara A, et al. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers. Eur J Cardiothorac Surg. 2017;52(1):55–62. doi:10.1093/ejcts/ezx04928369376
   PubMed Web of Science ®Google Scholar
• Abrahamsson J, Aaltonen K, Engilbertsson H, et al. Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: association with tumor stage, lymph node metastases, FDG-PET findings, and survival. Urol Oncol. 2017;35(10):606e609–606e616. doi:10.1016/j.urolonc.2017.05.021
   Web of Science ®Google Scholar
• Han D, Chen K, Che J, Hang J, Li H. Detection of epithelial-mesenchymal transition status of circulating tumor cells in patients with esophageal squamous carcinoma. Biomed Res Int. 2018;2018:7610154. doi:10.1155/2018/761015430046606
   PubMed Web of Science ®Google Scholar
• Zeng YE, Yao XH, Yan ZP, Liu JX, Liu XH. Potential signaling pathway involved in sphingosine-1-phosphate-induced epithelial-mesenchymal transition in cancer. Oncol Lett. 2016;12(1):379–382. doi:10.3892/ol.2016.466127347154
   PubMed Web of Science ®Google Scholar
• Zeng Y, Yao X, Chen L, et al. Sphingosine-1-phosphate induced epithelial-mesenchymal transition of hepatocellular carcinoma via an MMP-7/syndecan-1/TGF-beta autocrine loop. Oncotarget. 2016;7(39):63324–63337. doi:10.18632/oncotarget.1145027556509
   PubMedGoogle Scholar
• Yin LC, Luo ZC, Gao YX, Li Y, Peng Q, Gao Y. Twist expression in circulating hepatocellular carcinoma cells predicts metastasis and prognoses. Biomed Res Int. 2018;2018:3789613. doi:10.1155/2018/378961330046595
   PubMed Web of Science ®Google Scholar
• Qi LN, Xiang BD, Wu FX, et al. Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients with hepatocellular carcinoma. Cancer Res. 2018;78(16):4731–4744. doi:10.1158/0008-5472.CAN-17-245929915159
   PubMed Web of Science ®Google Scholar
• Liu YK, Hu BS, Li ZL, He X, Li Y, Lu LG. An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients. Hepatol Int. 2016;10(4):640–646. doi:10.1007/s12072-016-9732-727115761
   PubMed Web of Science ®Google Scholar
• Jin XR, Zhu LY, Qian K, et al. Circulating tumor cells in early stage lung adenocarcinoma: a case series report and literature review. Oncotarget. 2017;8(14):23130–23141. doi:10.18632/oncotarget.1550628423562
   PubMedGoogle Scholar
• Ou H, Huang Y, Xiang L, et al. Circulating tumor cell phenotype indicates poor survival and recurrence after surgery for hepatocellular carcinoma. Dig Dis Sci. 2018. doi:10.1007/s10620-018-5124-2
   Web of Science ®Google Scholar
• King JD, Casavant BP, Lang JM. Rapid translation of circulating tumor cell biomarkers into clinical practice: technology development, clinical needs and regulatory requirements. Lab Chip. 2014;14(1):24–31. doi:10.1039/c3lc50741f24190548
   PubMed Web of Science ®Google Scholar
• Alixpanabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor dna as liquid biopsy. Cancer Discov. 2016;6(5):479–491. doi:10.1158/2159-8290.CD-15-148326969689
   PubMed Web of Science ®Google Scholar
• Bork U, Rahbari NN, Scholch S, et al. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer. 2015;112(8):1306–1313. doi:10.1038/bjc.2015.8825867263
   PubMed Web of Science ®Google Scholar
• Lecharpentier A, Vielh P, Perezmoreno P, Planchard D, Soria JC, Farace F. Detection of circulating tumour cells with a hybrid (epithelial/mesenchymal) phenotype in patients with metastatic non-small cell lung cancer. Br J Cancer. 2011;105(9):1338–1341. doi:10.1038/bjc.2011.40521970878
   PubMed Web of Science ®Google Scholar
• Mego M, Mani SA, Lee BN, et al. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: the effect of neoadjuvant therapy. Int J Cancer. 2012;130(4):808–816. doi:10.1002/ijc.2603721387303
   PubMed Web of Science ®Google Scholar
• Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339(6119):580–584. doi:10.1126/science.122852223372014
   PubMed Web of Science ®Google Scholar